Trial
NCT04036461
A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Celgene
Collaborators
—
Condition
Multiple Myeloma
Intervention
CC-99712
Why stopped
Slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-08-30